These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37577920)

  • 1. The safety of the combination therapy of recombinant factor VIIa and plasma-derived factor VIIa and factor X for refractory hemorrhage in acquired hemophilia A.
    Okayama Y; Bingo M; Sakatoku K; Okamura H; Nanno S; Nishimoto M; Nakashima Y; Koh H; Hino M; Nakamae H
    Blood Coagul Fibrinolysis; 2023 Sep; 34(6):419-422. PubMed ID: 37577920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma-derived factors VIIa and X mixtures (Byclot
    Ochi S; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2020 Jun; 111(6):779-785. PubMed ID: 32030609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
    Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
    J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study.
    Zhang XH; Zhu XL; Niu T; Sun J; Liu H; Feng R; Yang LH; Wei Q; Ma QH; Wang QM; Feng FE; Fu HX; Mo XD; Lv M; Huang XJ
    Thromb Res; 2015 May; 135(5):835-40. PubMed ID: 25747536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
    Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
    Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report.
    Ma H; Chang H
    Medicine (Baltimore); 2021 Jan; 100(3):e24025. PubMed ID: 33545998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.
    Shirayama R; Takedani H; Chikasawa Y; Ishiguro A; Ishimura M; Isobe K; Uchiba M; Ogata Y; Kakuda H; Kusuhara K; Shirahata A
    Blood Coagul Fibrinolysis; 2019 Dec; 30(8):385-392. PubMed ID: 31738288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
    Keeney M; Allan DS; Lohmann RC; Yee IH
    Lab Hematol; 2005; 11(2):118-23. PubMed ID: 16024335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
    Iorio A; Matino D; D'Amico R; Makris M
    Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent.
    Nakatomi Y; Nakashima T; Gokudan S; Miyazaki H; Tsuji M; Hanada-Dateki T; Araki T; Tomokiyo K; Hamamoto T; Ogata Y
    Thromb Res; 2010 May; 125(5):457-63. PubMed ID: 20080285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
    Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
    Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO; Dazzi H; von Felten A
    Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant activated factor VII therapy in acquired hemophilia of the elderly.
    Dragani A; Di Bartolomeo E; La Barba G; Cavoni A; Lanzillotta P; Guizzardi G; Davì G
    Aging Clin Exp Res; 2004 Dec; 16(6):487-9. PubMed ID: 15739602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice.
    Holmberg HL; Lauritzen B; Tranholm M; Ezban M
    J Thromb Haemost; 2009 Sep; 7(9):1517-22. PubMed ID: 19566792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
    Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
    J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
    Matino D; Makris M; Dwan K; D'Amico R; Iorio A
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.